BioVie
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 13
- Market Cap
- -
- Introduction
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.
NE3107 in Adults With Neurological Symptoms of Long COVID
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- BioVie Inc.
- Target Recruit Count
- 208
- Registration Number
- NCT06847191
- Locations
- ๐บ๐ธ
Clinical Trial Site, Farmington Hills, Michigan, United States
A Study of NE3107 in Early Parkinson's
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- BioVie Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06757010
- Locations
- ๐บ๐ธ
Invicro, New Haven, Connecticut, United States
๐บ๐ธNorthwestern Medicine, Chicago, Illinois, United States
๐บ๐ธQuest Research Institute, Farmington Hills, Michigan, United States
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- BioVie Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05083260
- Locations
- ๐บ๐ธ
Parkinson's Disease & Movement Disorders Center Of Boca Raton, Boca Raton, Florida, United States
๐บ๐ธCharter Research, Winter Park, Florida, United States
๐บ๐ธUniversity of Toledo, Toledo, Ohio, United States
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- BioVie Inc.
- Target Recruit Count
- 439
- Registration Number
- NCT04669028
- Locations
- ๐บ๐ธ
The Ohio State University, Columbus, Ohio, United States
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
- Conditions
- AscitesDecompensated Cirrhosis
- Interventions
- Drug: BIV201 continuous infusion
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- BioVie Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04112199
- Locations
- ๐บ๐ธ
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธMercy Medical Center, Baltimore, Maryland, United States
Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
- Conditions
- CirrhosisAscites Hepatic
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- BioVie Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03107091
- Locations
- ๐บ๐ธ
Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States